Fig. 3
From: Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases
CLANmCas9/gNLRP3-mediated NLRP3 knockout and inflammasome inactivation in vitro. a, b Immunoblot analysis of cell lysates (Lys.) and supernatants (Sup.) (a) or cross-linked cytosolic pellets (b) from BMDMs transfected with CLANmCas9/gNLRP3 or other formulations and then primed with LPS and stimulated with nigericin. c–e ELISA of IL-1β (c), IL-18 (d), TNF-α (e) secretion from BMDMs transfected with CLANmCas9/gNLRP3 or other formulations and then primed with LPS and stimulated with nigericin. f, g Immunoblot analysis of cell lysates and supernatants (f) or ELISA of IL-1β secretion (g) from BMDMs transfected with CLANmCas9/gNLRP3 or CLANmCas9/gNC at the dose of 2.6 nM mCas9 and then primed with LPS and stimulated with MSU, nigericin, ATP or silica. The data are representative of three independent experiments (a, b, f) or are shown as the means ± SEM of n = 5 (c–e, g). Two-way ANOVA (c–e) Student’s t-test (g) *P < 0.05, ***P < 0.001, n.s. not significant
